Clinical Trial Details
— Status: Completed
Administrative data
| NCT number |
NCT02750163 |
| Other study ID # |
FreeHb |
| Secondary ID |
|
| Status |
Completed |
| Phase |
|
| First received |
|
| Last updated |
|
| Start date |
July 5, 2017 |
| Est. completion date |
June 5, 2019 |
Study information
| Verified date |
April 2019 |
| Source |
Università Politecnica delle Marche |
| Contact |
n/a |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Observational
|
Clinical Trial Summary
The aim of this study is to evaluate the effect of Acetaminophen on the main parameters of
microcirculation, on the plasmatic levels of free hemoglobin/oxidative stress markers and on
the expression of PD1/Pd-L1, in pyrexial septic patient.
Description:
It has been established that plasma levels of extra-cellular free hemoglobin increased
significantly in patients with certain disease, including sickle cellular disease, or
undergoing invasive treatments, like coronary bypass surgery, blood transfusions and
hemodialysis.
In all these conditions, high levels of free hemoglobin were associated with poor outcome and
with serious complications such as acute renal failure and myocardial infarction.
In the animal model of sepsis, increased values of plasma free hemoglobin has been related to
increased mortality, especially if a concomitant lack of haptoglobin and hemopexin coexists.
It is likely that the release of free hemoglobin in the blood of septic patient is
attributable to changes in the membrane of red blood cells.
These changes have been recognized in humans as a source of damage of the vascular
endothelium and consumption of free radical scavenger systems.
It has been hypothesized that the extracellular hemoglobin, when the protective mechanism
have been saturated, causes - trough reaction with NO - the formation of nitrate and lipids
peroxidation and boosts the immune response mediated by the monocyte -macrophage system.
It is also liable for a condition of endothelial dysfunction and NO resistance that could
impair the microcirculation.
Our previous work showed that higher levels of free hemoglobin resulted in a significant
reduction in the density of the microcirculation in septic patients undergoing blood
transfusions.
On animal model Paracetamol (or acetaminophen), drug commonly used for its analgesic and
antipyretic effects, demonstrated strong efficacy in preventing oxidative damage and
protection of renal damage in the context of increased levels of plasma free hemoglobin (as
in Rhabdomyolysis and myoglobulinemie).
This effect is attributed to the ability of the Paracetamol to cross react with either nitric
oxide synthase (NOS) by increasing the synthesis of NO, and with cyclooxygenase (COX), by
inhibiting the synthesis of prostaglandin I2 (PGI2-antiplatelet and vasodilator effect)
without interfering with the production of Thromboxane A2 (TXA2-powerful vasoconstrictor and
pro-thrombogenic) causing an imbalance of endovascular homeostasis.
The increased oxidative stress produced by sepsis is also responsible of glycocalix damage,
the thin layer that lines the surface of endothelium in contact with the blood and increased
the free hemoglobin.
ROS are also responsible to up-regulation of Programmed Death-1 related molecules
(PD-1/PD-L1) that render T cells susceptible to inhibitory modulation, inability to
proliferate and reduced capacity to clear bacteria, inducing "immunosuppression" and more
difficult recovery from septic shock. PD-1/PD-L1 system has been recently studied as
potential predictor of mortality and active player in resolution of sepsis-induced Acute Lung
Injury.
Finally, a recent study on septic patient showed an increased mortality in people with
elevated values of free hemoglobin versus patients without this increase, and the efficacy of
of Paracetamol to reduce the concentration of F2- isoprostane (marker of oxidative stress),
associated with lower risk of death.
This effect was lost in the cohort of septic patients without free hemoglobin registered.
Aim of this study is to evaluate the effect of paracetamol administration on the
microcirculation, on the plasmatic levels of free hemoglobin/oxidative stress markers and on
the expression of PD1/Pd-L1, in pyrexial septic patient. Paracetamol is given only on the
basis of a clinical indication, not because of the study and in our institution paracetamol
is the drug of choice to treat fever.
When there are inclusion criteria (febrile septic patient) and no exclusion criteria, and
patient is going to receive paracetamol, informed consent will be taken. When the
neurological conditions do not permit, relatives will be informed and the patients will still
included in the protocol. The informed consent will be taken when the patient clinical
condition permits it.
Before the administration of the drug, at the end of infusion and after 30 minutes after
infusion, the main parameters of the sublingual microcirculation will be monitored, using the
the incident dark field imaging technique (IDF), including an assessment of glycocalyx, Near
InfraRed (NIRS) parameters with the vascular occlusion test (VOT), vital signs and the dosage
of any infusion of vasoactive drug.
Demographic and clinical records will be collected at T0 and T1. Acute lung injury will be
investigated through gas analytical and laboratory data at the same timepoints.
Arterial blood samples will be collected at T0 and 2 hours after the infusion of
Acetaminophen (that will represent T2). Blood will be immediately centrifuged and plasma and
serum samples will be stored at -70°C for subsequent analysis. We will measure: fHb levels,
markers of oxidative damage (F2-isoprastane and F2-isoflurane), of endothelial cell injury
(endothelin-1) and glycocalyx damage (sindecan-1, heparasulfate), PD-1/PD-L1.
